Oncternal Therapeutics Inc
ONCT
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.56M
Close$
$0.12
77.7% downside
Current Fair Value
77.7% downsideOvervalued by 77.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.56 Million |
|---|---|
| Enterprise Value | $-11,520,454.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-13.43 |
| Beta | 1.36 |
| Outstanding Shares | 2,960,000 |
Return
| Return on Equity | -377.95% |
|---|---|
| Return on Assets | -221.62% |
| Return on Invested Capital | -594.38% |
Valuation & Multiples
| P/E Ratio | -0.04 |
|---|---|
| PEG | 0.28 |
| Price to Sales | - |
| Price to Book Ratio | 0.18 |
| Enterprise Value to Revenue | -13.3 |
| Enterprise Value to EBIT | 0.21 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Oncternal Therapeutics Inc
CEO: James Breitmeyer